Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 2/3 1

Status

Completed 27Unknown 8Terminated 5Active not recruiting 5Recruiting 4Not yet recruiting 3Withdrawn 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 4Tumor-Agnostic 1

Conditions

Colorectal Neoplasms 2Stomach Neoplasms 1Neoplasm Metastasis 1Metastatic Colorectal Adenocarcinoma 1

Interventions

pembrolizumab 198Nivolumab 146Carboplatin 133Specimen Handling 130Magnetic Resonance Spectroscopy 116Cyclophosphamide 112Paclitaxel 106Biopsy 97Cisplatin 94Radiotherapy 89durvalumab 83Dexamethasone 80atezolizumab 73Ipilimumab 66Gemcitabine 60Doxorubicin 60Rituximab 59Lenalidomide 56Docetaxel 55olaparib 51Etoposide 51Bevacizumab 51Fluorouracil 49Capecitabine 49Radiation 47Oxaliplatin 47Radiosurgery 43Prednisone 43venetoclax 41Taxes 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Active not recruiting × IFL protocol × Clear all
NCT04587128 2026-02-05

Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC

University of Wisconsin, Madison

Phase 2 Active not recruiting
34 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT06106308 2026-01-12

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation

Cardiff Oncology

Phase 2 Active not recruiting
113 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT03806309 2025-07-25

TEDOPAM

GERCOR - Multidisciplinary Oncology Cooperative Group

Phase 2 Active not recruiting
106 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT05312398 2025-05-25

CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen

University of Campania Luigi Vanvitelli

Phase 2 Active not recruiting
219 enrolled
Gastrointestinal

Metastatic Colorectal Adenocarcinoma

NCT03959293 2024-07-08

Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma

Federation Francophone de Cancerologie Digestive

Phase 2 Active not recruiting
107 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡